NEW YORK (GenomeWeb) – Becton Dickinson today reported a 2 percent year over year increase in fiscal first quarter revenues as growth in both its Life Sciences and Medical segments was tempered by an unfavorable currency impact.

For the three months ended Dec. 31, BD reported revenues of $2.05 billion compared to $2.02 billion in the same quarter last year and beating analysts' consensus estimate of $2.01 billion. On a currency-neutral basis, revenues increased about 5 percent year over year, BD said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.